Catalog Number : 500-P260
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hPAI-1 (human Plasminogen Activator Inhibitor-1). Anti-Human PAI-1 specific antibody was purified by affinity chromatography employing immobilized hPAI-1 matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human PAI-1 (BioGems Catalog #140-04)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 62.5 ng/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.
*Additional Immunostaining data available. Please contact Tech Support for information.
To yield one-half maximal inhibition [ND50] of the biological activity of hPAI-1 (4.5 μg/ml), a concentration of at least 15.0 μg/ml of this antibody is required.
To detect hPAI-1 by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human PAI-1 (60-263BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hPAI-1.
To detect hPAI-1 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hPAI-1 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.